Adherence to therapy with oral antineoplastic agents

Journal of the National Cancer Institute

Volumn 94, Issue 9, 2002, Pages 652-661

  Partridge, Ann H ^a   Avorn, Jerry ^a   Wang, Philip S ^a   Winer, Eric P ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 OXOSTEROID; ALLOPURINOL; ALTRETAMINE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; ENZYME INHIBITOR; ESTROGEN; ETOPOSIDE; FLUDARABINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; IDARUBICIN; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NAVELBINE; PENICILLIN G; PRASTERONE SULFATE; PREDNISOLONE; PREDNISONE; PROCARBAZINE; STEROID; TAMOXIFEN; TAXANE DERIVATIVE; UNINDEXED DRUG;

ADOLESCENT; ADULT; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CHILD; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG USE; HEALTH BEHAVIOR; HODGKIN DISEASE; HUMAN; LUNG SMALL CELL CANCER; MYELOID LEUKEMIA; NONHODGKIN LYMPHOMA; OVARY CANCER; PATIENT COMPLIANCE; POPULATION RESEARCH; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

EID: 0036566758     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/94.9.652     Document Type: Review

References (109)

1. The pharmacology of intravenous and oral etoposide
2. Patient preferences for oral versus intravenous palliative chemotherapy
3. Chronobiology. Suggestions for integrating it into drug development
4. Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil
5. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer
6. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: In-vivo imaging of drug action
7. Noncompliance: The ultimate absorption barrier
8. Compliance in health care
9. Symptoms associated with tamoxifen treatment in postmenopausal women
10. Compliance with therapeutic regimens
11. Intentional prescription nonadherence (noncompliance) by the elderly
12. Adherence to treatment and health outcomes
13. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring
14. Persistence of use of lipid-lowering medications: A cross-national study
15. Angiotensin-converting enzyme inhibitor compliance and dosing among patients with heart failure
16. Compliance with antihypertensive therapy among elderly Medicaid enrollees: The roles of age, gender, and race
17. Patients' cooperation with a medical regimen. Difficulties in identifying the noncooperator
18. The problem of non-compliance with drug therapy
19. Treatment compliance in childhood and adolescence
20. The drug defaulter
21. Patient noncompliance with self-administered chemotherapy
22. Overview of patient compliance with medication dosing: A literature review
23. Dose-response effect of adjuvant chemotherapy in breast cancer
24. Compliance and clinical trials
25. Evaluation of a novel medication aid, the calendar blister-pack, and its effect on drug compliance in a geriatric outpatient clinic
26. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care
27. Measurement of patient compliance and the interpretation of randomized clinical trials
28. Health behaviors and pharmacotherapy
29. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer
30. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
31. Intensive postremission chemotherapy in adults with acute myeloid leukemia
32. Improved survival for childhood acute lymphoblastic leukemia: Possible effect of protocol compliance
33. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer
34. Tamoxifen for early breast cancer: An overview of the randomized trials
35. Sociobehavioral determinants of compliance
36. Noncompliance with antihypertensive medications: The impact of depressive symptoms and psychosocial factors
37. A critical review of the "determinants" of patient compliance with therapeutic regimens
38. The health behavior model and personal health behavior
39. Why people use health services
40. Self-efficacy: Toward a unifying theory of behavioral change
41. Generalized expectancies for internal locus of control of reinforcement
42. Compliance declines between clinic visits
43. The patient's view of hypertension and compliance
44. Adherence to medication regimens: Updating a complex medical issue
45. The effect of prescribed daily dose frequency on patient medication compliance
46. Dosage frequency and drug-compliance behaviour-a comparative study on compliance with a medication to be taken twice or four times daily
47. Evaluation of family health education to build social support for long-term control of high blood pressure
48. Randomised clinical trial of strategies for improving medication compliance in primary hypertension
49. Predictors of medication adherence in the elderly
50. Risk factors for antihypertensive medication refill failure by patients under Medicaid managed care
51. A reliable method for evaluating drug compliance in children with cancer
52. Compliance of pediatric and adolescent cancer patients
53. Profile of non-compliance in lymphoblastic leukaemia
54. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly
55. Initiation of and adherence to treatment for mental disorders: Examination of patient advocate group members in 11 countries
56. Recent care of common mental disorders in the United States: Prevalence and conformance with evidence-based recommendations
57. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders
58. Renal transplant patient compliance with free immunosupressive medications
59. The effect of a copay increase on pharmaceutical utilization, expenditures, and treatment continuation
60. Effects of user charges on the use of prescription medicines in different socio-economic groups
61. The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy
62. Patient compliance with oral chemotherapy as assessed by a novel electronic technique
63. Communication, compliance, and concordance between physicians and patients with prescribed medications
64. Doctor-patient communication: A review of the literature
65. Evidence on patient-doctor communication
66. In search of the gold standard for compliance measurement
67. A critical evaluation of the methodology of the literature on medication compliance
68. Monitoring universal precautions: A new assessment tool
69. The social problems of an industrialized civilization
70. A dictionary of epidemiology
71. Compliance with oral drug therapy in patients with hematologic malignancy
72. Can simple clinical measurements detect patient noncompliance?
73. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy
74. Time to stop counting the tablets?
75. The natural history of medication compliance in a drug trial: Limitations of pill counts
76. How often is medication taken as prescribed? A novel assessment technique
77. Role of patient compliance in clinical pharmacokinetics. A review of recent research
78. Therapeutic adherence to oral medication regimens by adolescents with cancer. I. Laboratory assessment
79. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer
80. Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer
81. The accuracy of Medicare's hospital claims data: Progress has been made, but problems remain
82. Pill count, self-report, and pharmacy claims data to measure medication adherence in the elderly
83. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors
84. Tamoxifen therapy in early breast cancer: Biology, efficacy, and side effects
85. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation
86. Randomized 2×2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients
87. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: Different compliance with treatment
88. The behavioral dynamics of clinical trials
89. Prospects for antiestrogen chemoprevention of breast cancer
90. Psychological correlates of compliance
91. Intracellular metabolites of mercaptopurine in children with lymphoblastic leukaemia: A possible indicator of non-compliance?
92. Therapeutic adherence to oral medication regimens by adolescents with cancer. II. Clinical and psychologic correlates
93. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia
94. Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy
95. Special aspects of cancer prevention trials
96. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease
97. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study
98. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: Effects of base-line characteristics and study compliance
99. Correcting for non-compliance in randomized trials: An application to the ATBC Study
100. Predictors of inactivation and reasons for participant inactivation during a skin cancer chemoprevention study
101. The importance and nature of cancer prevention trials
102. A review of breast cancer chemoprevention
103. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
104. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
105. Drug defaulting in a general practice
106. Drug therapy: Patient compliance
107. Oral chemotherapeutic agents for colorectal cancer
108. Effectiveness of interventions to improve patient compliance: A meta-analysis